GSK’s Cabotegravir Receives NMPA Approval for HIV Treatment in China
The National Medical Products Administration (NMPA) has granted marketing approval for GlaxoSmithKline’s (GSK, NYSE: GSK)...
Beijing Tinavi Medical’s Knee Replacement Navigation System Approved by NMPA
Beijing Tinavi Medical Technologies Co., Ltd (SHA: 688277) has received marketing approval from the National...
GeneQuantum Healthcare and Aimed Bio Expand Partnership to Develop Five Novel ADC Drugs
China-based GeneQuantum Healthcare has unveiled a new agreement to expand its existing partnership with South...
BeiGene’s Brukinsa Receives US FDA Review for Relapsed/Refractory Follicular Lymphoma sNDA
China-based biotechnology company BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration...
AstraZeneca and Daiichi Sankyo’s Enhertu Gains New Indication Approval in China for HER2-Low Breast Cancer
Partners AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have announced that their co-developed...
US FDA Approves Additional Shipments of Qilu Pharmaceutical’s Cisplatin to Address Shortage
The US Food and Drug Administration (FDA) is maintaining its reliance on China-based Qilu Pharmaceutical...
Shanghai Fosun Pharmaceutical Submits Tenapanor Approval Application to China’s NMPA
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a...
DNE Group Launches $485 Million Fund for Life Sciences Park in Shanghai Pudong
China-based infrastructure investor DNE Group has revealed that it has raised a new fund worth...
LianBio Secures Clinical Supply Agreement with AstraZeneca for SHP2 Inhibitor Trial
Sino-US biotech firm LianBio (OTCMKTS: LIANY) has announced the signing of a clinical supply agreement...
Medidata Partners with ECCO and GoBroad to Transform Cancer Trials with Digital Tech
Medidata, a wholly owned subsidiary of France firm Dassault Systèmes (EPA: DSY), has announced a...
Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential
Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE)...
Kedrion Biopharma Achieves First Product Approval in China for Human Albumin
Italy-headquartered blood products specialist Kedrion Biopharma has announced that its subsidiary, Bio Products Laboratory (BPL),...
GRIT Biotechnology’s GT201 TIL Therapy Approved for Clinical Studies by China’s CDE
The Center for Drug Evaluation (CDE) website has indicated that GRIT Biotechnology, a China-based cell...
Novartis Terminates TIGIT-Targeted Antibody Deal with BeiGene, Retains Rights to Ociperlimab
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has decided to terminate an option and license...
Biocytogen Pharmaceuticals Awarded CNIPA Patent for RenMab Human Antibody Mice Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based biopharmaceutical company, has announced receiving a...
Guangdong’s OptoMedic Secures Over $27.8 Million in Pre-IPO Financing for Endoscopy Innovations
OptoMedic Technologies, Inc., a leading endoscopy specialist based in Guangdong, has reportedly raised upwards of...
Jiangsu Hengrui Pharmaceuticals’ Irinotecan and Bupivacaine Liposome Injections Get Clinical Trial Green Light in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving separate...
Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...
Jiangsu Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Irinotecan and Bupivacaine Liposome Injections
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving separate...
Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...